期刊
ONCOLOGIST
卷 26, 期 11, 页码 974-982出版社
OXFORD UNIV PRESS
DOI: 10.1002/onco.13944
关键词
Chronic myeloid leukemia; Tyrosine kinase inhibitors; Vascular adverse events
类别
资金
- Ministry of Science and Technology, Taiwan [MOST 108-2314-B-002-118-MY3]
This study found that patients with chronic myeloid leukemia (CML) treated with nilotinib had a significantly higher risk of developing vascular adverse events (VAEs) compared to those treated with imatinib, while dasatinib users also showed a trend for VAE development. Nilotinib usage, older age, and history of cerebrovascular diseases were identified as significant risk factors for VAEs.
Background Tyrosine kinase inhibitors (TKIs) have shown long-term survival benefits in patients with chronic myeloid leukemia (CML). Nevertheless, significant concern has been raised regarding long-term TKI-associated vascular adverse events (VAEs). The objective of this retrospective cohort study was to investigate the incidence of VAEs in Taiwanese patients with CML treated with different TKIs (imatinib, nilotinib, and dasatinib) as well as potential risk factors. Materials and Methods We conducted a retrospective cohort study using the Taiwan Cancer Registry Database and National Health Insurance Research Database. Adult patients diagnosed with CML from 2008 to 2016 were identified and categorized into three groups according to their first-line TKI treatment (imatinib, nilotinib, and dasatinib). Propensity score matching was performed to control for potential confounders. Cox regressions were used to estimate the hazard ratio (HR) of VAEs in different TKI groups. Results In total, 1,111 patients with CML were included in our study. We found that the risk of VAEs in nilotinib users was significantly higher than that in imatinib users, with an HR of 3.13 (95% confidence interval (CI), 1.30-7.51), whereas dasatinib users also showed a nonsignificant trend for developing VAEs, with an HR of 1.71 (95% CI, 0.71-4.26). In multivariable logistic regression analysis, only nilotinib usage, older age, and history of cerebrovascular diseases were identified as significant risk factors. The annual incidence rate of VAEs was highest within the first year after the initiation of TKIs. Conclusion These findings can support clinicians in making treatment decisions and monitoring VAEs in patients with CML in Taiwan. Implications for Practice This study found that patients with chronic myeloid leukemia (CML) treated with nilotinib and dasatinib may be exposed to a higher risk of developing vascular adverse events (VAEs) compared with those treated with imatinib. Thus, this study suggests that patients with CML who are older or have a history of cerebrovascular diseases should be under close monitoring of VAEs, particularly within the first year after the initiation of tyrosine kinase inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据